Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Neurology"
DOI: 10.1007/s00415-021-10664-w
Abstract: Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS… read more here.
Keywords: alemtuzumab nationwide; safety; safety alemtuzumab; cohort ... See more keywords